Physician

Haresh S. Jhangiani, M.D.

According to 2025 Medicare claims, Haresh Jhangiani, M.D. (NPI: 1578566998) practices hematology/oncology in the Anaheim-Santa Ana-Irvine, CA market, with the plurality of this provider's patient population coming from Orange, CA. This provider's primary affiliated billing organization is LOS ANGELES HEMATOLOGY-ONCOLOGY MEDICAL GROUP (NPI: 1457409674; TIN: 95-4332724) and primary practice location at 92708-7516. Jhangiani is affiliated with the Family Choice ACO, LLC (ACO ID: A3770), participating under the MSSP model.

Jhangiani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 177 traditional Medicare patients, billed 64,257 HCPCS/CPT codes, and received $1,471,298 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 1,208 prescription claims across 193 beneficiaries totaling $2,830,150 in drug costs, led by Xtandi (Enzalutamide). 2021 DME data shows 11 claims. Open Payments data shows 336 records totaling $91,739. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $968,622 and ending at $1,471,298. Concurrently, Part D prescription costs have risen steadily, from $1,731,164 to $2,830,150. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	250	110,467	$968,622
2016	248	123,940	$1,276,534
2017	244	90,725	$1,094,179
2018	217	76,465	$858,136
2019	191	102,918	$1,317,949
2020	170	136,114	$1,922,364
2021	177	108,014	$1,891,839
2022	179	66,216	$1,313,332
2023	150	52,158	$1,106,701
2024	177	64,257	$1,471,298

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	154	800	$1,731,164
2016	146	767	$1,326,080
2017	142	607	$1,131,792
2018	161	771	$1,529,319
2019	161	862	$2,639,102
2020	160	783	$1,889,900
2021	148	654	$1,735,926
2022	157	727	$2,623,389
2023	163	733	$2,116,071
2024	193	1,208	$2,830,150

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	43	$6,167
2016	N/R	106	$29,936
2017	N/R	53	$11,301
2018	N/R	54	$4,112
2019	N/R	14	$1,847
2020	N/R	12	$1,539
2021	N/R	11	$1,298
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	53	108	$150
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	163	497	$97
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	35	54	$49
36415	Insertion of needle into vein for collection of blood sample	60	143	$9
96127	Assessment of emotional or behavioral problems	110	115	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	32	960	$444,076
Pomalyst	Pomalidomide	16	441	$362,326
Enhertu	Fam-Trastuzumab Deruxtecn-Nxki	21	441	$223,978
Lupron Depot	Leuprolide Acetate	40	3,066	$201,441
Darzalex Faspro	Daratumumab-Hyaluronidase-Fihj	13	364	$122,179

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	309	$12,456	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	27	$79,283	Janssen Research & Development, LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Haresh S. Jhangiani, M.D.?

Tedicare shows public-source Medicare data for Haresh S. Jhangiani, M.D. (NPI 1578566998), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Haresh S. Jhangiani, M.D. have ACO affiliation data?

Haresh S. Jhangiani, M.D. is shown with ACO affiliation data for Family Choice ACO, LLC (MSSP, ACO ID A3770).

What billing organization is linked to Haresh S. Jhangiani, M.D.?

Haresh S. Jhangiani, M.D. is linked to LOS ANGELES HEMATOLOGY-ONCOLOGY MEDICAL GROUP (billing NPI 1457409674) in the available physician profile data.

Does Haresh S. Jhangiani, M.D. have Open Payments data?

Haresh S. Jhangiani, M.D. has 336 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.